| Published Version Download ( PDF | 96kB) |
Targeted agents in patients with recurrent glioblastoma– a systematic meta-analysis of randomized clinical trials
Article
Ippen, Franziska Maria
, Scherm, Angelika, Kessler, Tobias, Hau, Peter
, Baurecht, Hansjörg
, Wick, Wolfgang, Knüttel, Helge
, Leitzmann, Michael F.
and Seliger, Corinna
(2023)
Targeted agents in patients with recurrent glioblastoma– a systematic meta-analysis of randomized clinical trials.
Neuro-Oncology 25 (Supp.5), v116.
DOI to cite this document: 10.5283/epub.55201
Abstract
BACKGROUND Glioblastoma (GB) is the most common malignant primary brain tumor in adults and associated with a dismal prognosis. While the standard of care for newly diagnosed GB is defined in current treatment guidelines, recommendations for recurrent GB are less well established. The current systematic meta-analysis of recently published randomized controlled trials (RCTs) represents the ...
BACKGROUND
Glioblastoma (GB) is the most common malignant primary brain tumor in adults and associated with a dismal prognosis. While the standard of care for newly diagnosed GB is defined in current treatment guidelines, recommendations for recurrent GB are less well established. The current systematic meta-analysis of recently published randomized controlled trials (RCTs) represents the strongest available evidence on targeted agents in patients with recurrent GB.
METHODS
Cochrane Library, Pubmed, MEDLINE (Ovid), ClinicalTrials.gov, WHO's International Clinical Trials Registry Platform and Google Scholar were searched ranging from the year 1954-2022 for RCTs of targeted therapies in patients with recurrent GB. Hazard Ratios (HRs) of overall survival (OS) and progression-free survival (PFS) were extracted to perform a random-effects meta-analysis.
RESULTS
16 RCTs (n=3,025 patients) were included in the meta-analysis. Experimental treatment was either compared to lomustine (CCNU) alone, in combination with CCNU/temozolomide (TMZ) to CCNU alone or to bevacizumab alone. In these three subgroups, targeted agents associated with improved OS compared to the control arm were regorafenib (RR= 0.50; 95% CI 0.33-0.75), Depatux- M+ TMZ (RR= 0.66; 95% CI 0.44-0.93) and rindopepimut + bevacizumab (RR= 0.53; 95% CI 0.32-0.88). Treatment with bevacizumab + CCNU (RR= 0.49; 95% CI 0.35-0.69) and regorafenib (RR= 0.65; 95% CI 0.44-0.95) were associated with improved PFS.
CONCLUSION
In this systematic meta-analysis, we provide the current highest level of evidence for the role of targeted therapies in recurrent GB. Even though some studies revealed a benefit either for OS and/or PFS, results have to be critically reviewed regarding initial distribution of prognostic factors, underlying molecular mechanisms, sample size and trial design. There is a need for more specific and personalized study designs using newly obtained tumor tissue and close monitoring of treatment responses to allow for potential modification of treatment if needed.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Neuro-Oncology | ||||
| Publisher | Oxford Univ. Press | ||||
| Volume | 25 | ||||
| Number of Issue or Book Chapter | Supp.5 | ||||
| Page Range | v116 | ||||
| Date | 10 November 2023 | ||||
| Date of publication | 20 Dec 2023 08:36 | ||||
| Additional Information (public) | Abstract from the 2023 Society for Neuro-Oncology’s 28th Annual Scientific Meeting and Education Day | ||||
| Institutions | Medicine > Lehrstuhl für Neurologie Medicine > Institut für Epidemiologie und Präventivmedizin Central Institutions > University Library | ||||
| Identification Number |
| ||||
| Keywords | glioblastoma; adult; lomustine; medline; arm; brain; neoplasms; bevacizumab; temozolomide; prognostic factors; treatment guidelines; cochrane collaboration; standard of care; experimental treatment; molecular targeted therapy; regorafenib; progression-free survival | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Partially | ||||
| URN of the UB Regensburg | urn:nbn:de:bvb:355-epub-552018 | ||||
| Item ID | 55201 |
Download Statistics
Download Statistics